All HIV articles – Page 5
-
NewsMultiple testing for infectious diseases among migrants key to cutting onward transmission
Routine testing for multiple infectious diseases among migrants will benefit healthcare systems by identifying key infections earlier, a new study finds.
-
NewsHIV discovery could open door to long-sought cure
Scientists have uncovered a key reason why HIV remains so difficult to cure: Their research shows that small changes in the virus affect how quickly or slowly it replicates, and how easily or stubbornly it can reawaken from hiding.
-
NewsNew diagnostic tool uses bioluminescence to detect viruses
Researchers are shining a powerful new light into the viral darkness with the development of Luminescence CAscade-based Sensor (LUCAS), a rapid, portable, highly-sensitive diagnostic tool for processing complex biological samples.
-
NewsPortable HIV monitoring device shows promise for remote settings
A newly developed microfluidic biosensor promises to reshape how CD4+ T cells — key indicators of immune function in Human Immunodeficiency Virus (HIV) patients — are detected.
-
NewsThe Global Fund to fight AIDS, Tuberculosis and Malaria ‘should step up efforts’
The international community must protect global responses to HIV, tuberculosis (TB), and malaria to serve humanity’s collective interests, according to a new opinion article.
-
NewsTwo HIV vaccine trials show proof of concept for pathway to broadly neutralizing antibodies
A new study combining data from two separate phase 1 clinical trials shows that a targeted vaccine strategy can successfully activate early immune responses relevant to HIV, and, in one trial, further advance them.
-
NewsProof of concept for HIV vaccination that deploys germline-targeting
For a preventative HIV-vaccine to work it should induce broadly neutralising antibodies against all the diverse strains of the virus. The first in-human assessment of germline-targeting strategy with a trimer displays positive results.
-
News‘Loop’hole: HIV-1 hijacks human immune cells using circular RNAs
In a groundbreaking discovery, researchers have identified a never-before-seen mechanism that enables the human immunodeficiency type 1 virus (HIV-1) to evade the body’s natural defenses and use it to support its survival and replication.
-
NewsScientists win award for bringing breakthrough HIV treatment lenacapavir into play
Three people have been awarded the AAAS Mani L. Bhaumik Breakthrough of the Year Award for their work on the first HIV drug to offer long-lasting protection from infection — eliminating the need for people to take a daily pill.
-
NewsNew CDC nPEP Guidelines should become ‘part of general medical practice’
Health experts say the updated CDC HIV Non-Occupational Post Exposure Prophylaxis (nPEP) Guidelines should be part of general medical practice, as incorporating them will reduce new HIV infections and improve public health.
-
NewsAntibodies that recognize lipids: A new path for HIV vaccines and autoimmune disease treatments
Scientists have used computer modeling to illustrate how a specific class of antibodies actually use lipids to recognize the HIV virus. The work highlights antibody features that could help people design better vaccines for HIV and autoimmune diseases.
-
NewsNew treatment for cryptococcal meningitis enters Phase II trial
Cryptococcal meningitis, the second-leading cause of HIV-related deaths, is expected to rise as access to care weakens and advanced HIV disease (previously called AIDS) increases.
-
NewsEliminating worm infections as a key strategy for HIV/AIDS prevention
Scientists who found that infection with the worm Wuchereria bancrofti increases the risk of contracting HIV have now confirmed, as part of a national program in Tanzania, that containment of this worm infection leads to a reduction in new HIV infections.
-
NewsNovel point-of-care technology delivers accurate HIV results in minutes
Scientists have developed new technology that could lead to the creation of a rapid point-of-care test for HIV infection competitive with traditional lab-based HIV testing in a fraction of the time and without the need for a stressful wait.
-
NewsMolecular stool test could improve detection of tuberculosis in adults with HIV
A prospective multicentre study highlights the potential of the Xpert MTB/Ultra stool test for diagnosing tuberculosis in people living with HIV.
-
NewsFAU secures $1.3 million NIH grant for breakthrough in HIV self-test technology
To address the urgent need for a reliable, rapid and affordable self-test for early HIV detection, researchers have been awarded phase-II of a five-year, $1.3 million grant which will support the development of an innovative disposable microchip technology designed for HIV-1 self-testing during the first two weeks post-infection.
-
NewsProposed cuts to foreign aid could result in millions of HIV deaths, new modelling study estimates
New modelling analysis suggests that proposed funding cuts by major donor countries to foreign aid could undo decades of progress made to end HIV/AIDS as a public health threat and new infections and deaths could surge back to levels not seen since the early 2000s.
-
NewsSimulation model shows potential affordability of preventative HIV therapy for infants
A type of cost-effective HIV neutralizing antibodies was evaluated to prevent the viral infection in infants during breastfeeding in high HIV prevalance countries. This treatment option is comparatively cheaper and has high clinical impacts in high HIV burden settings to achieve global elimination.
-
NewsJapanese plant Daphne pseudomezereum yields anti-HIV daphnane diterpenoids
Scientists have discovered for the first time that Daphne pseudomezereum (commonly known as Onishibari) contains a substance inhibiting replication of human immunodeficiency virus (HIV).
-
NewsStudy yields new data on Mpox vaccine effectiveness in people with HIV
A new study has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer sufficient protection. All at-risk groups, especially people with HIV, should receive the second dose of the vaccine as recommended.